Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056051 · ClinicalTrials.gov registry record · NA
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
A NA study of Esophageal Cancer and Barrett Esophagus, sponsored by Northwestern University.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT05056051: Recruiting NA study of Esophageal Cancer and Barrett Esophagus, sponsored by Northwestern University.
NCT05056051 is a NA study of Esophageal Cancer and Barrett Esophagus that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 200 participants, below the 497-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (60% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05056051, a NA study of Esophageal Cancer and Barrett Esophagus, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barrett's esophagus recurrence following treatment. Wide-Area Trans-Epithelial Sampling (WATS-3D) is a new technology that uses brush sampling to examine larger areas of the esophagus as compared to conventional biopsies. Preliminary studies show improved detection of cancerous changes in Barrett's esophagus surveillance. The investigators hope to see if the addition of WATS-3D increases the rate of detection of recurrent BE following treatment, which is of the utmost importance since it would allow for earlier re-treatment of disease and ultimately allow for prevention of progression to esophageal cancer.
Conditions Studied
Interventions
- DEVICE WATS-3D tissue sampling prior to forceps biopsies
- DEVICE WATS-3D tissue sampling following forceps biopsies
Study Locations (4)
California
- University of California, LA - Los Angeles
Colorado
- University of Colorado - Aurora
Illinois
- Northwestern Memorial Hospital - Chicago
Missouri
- Washington University in St. Louis, Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2025-06-30 |
| Phase | NA |
What NCT05056051 shows while recruiting
NCT05056051 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 497-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which WATS-3D tissue sampling prior to forceps biopsies is the first listed.
NCT05056051 reports a single indexed study location in California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT05056051 about?
NCT05056051 is a clinical study titled "Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus". Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barre...
What is the current status of trial NCT05056051?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2020-10-01. Estimated completion is 2025-06-30.
What conditions does trial NCT05056051 study?
This clinical trial studies the following conditions: Esophageal Cancer, Barrett Esophagus.
What interventions are being tested in trial NCT05056051?
The interventions under investigation include: WATS-3D tissue sampling prior to forceps biopsies (DEVICE), WATS-3D tissue sampling following forceps biopsies (DEVICE).
Who is sponsoring clinical trial NCT05056051?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05056051 being conducted?
This trial has 4 study locations across California, Colorado, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05056051's enrollment target sits among peer trials
200 34th of 123 higher than 85 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
RECRUITING · NA
-
Exercise Prehabilitation for Locoregional Esophageal Cancer
RECRUITING · NA
-
Resilience and Equity in Aging, Cancer, and Health (REACH)
RECRUITING · NA
-
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
RECRUITING · NA
-
Serial MRI Scans During Radiation Therapy
RECRUITING · NA
-
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI